Agenus Highlights Data from Five Studies of Botensilimab/Balstilimab (BOT/BAL) Regimen as Multiple lines of Therapy in Colorectal Cancer at ASCO GI 2025
Shots:
- P-II neoadj. studies were UNICORN (n=56) & NEST (n=24) in resectable CRC. UNICORN: 93% & 29% pCR with 100% & 36% pMR in dMMR/MSI-H & pMMR/MSS tumors, respectively; NEST: At 18 (NEST-1) & 9mos. (NEST-2) follow-up, all were ctDNA-ve w/o recurrences; pMR improved to 47% in MSS tumors in NEST-2
- P-I/II study of BOT/BAL with FOLFOX-Avastin in 1L MSS mCRC showed 71% ORR in 14 pts (12 treated with FOLFOX) & 67% in those with liver metastases
- Global P-II trial of BOT/BAL (75/150mg) in refractory MSS mCRC pts (n=234). 75mg depicted 19% ORR, 55% DCR & durable responses (70% ongoing at data cut-off) & will enter P-III. Another P-II trial of BOT/BAL/AgenT-797 with Cyramza & paclitaxel showed early activity in 2L metastatic GE cancers; data expected in H2’25
Ref: Businesswire | Image: Agenus
Related News:- Tris Pharma Reports the P-III (ALLEVIATE-1) Study Results of Cebranopadol to Treat Moderate-to-Severe Acute Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
